(Q34906412)

5 August 2017

1 reference

title

An overview of insulin glargine (English)

1 reference

5 August 2017

1 reference

Philip D Home

1

1 reference

5 August 2017

Simon G Ashwell

series ordinal

2

1 reference

5 August 2017

publication date

1 September 2002

1 reference

Diabetes - Metabolism: Research and Reviews

5 August 2017

published in

1 reference

5 August 2017

volume

18 Suppl 3

1 reference

5 August 2017

page(s)

S57-63

1 reference

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

5 August 2017

cites work

1 reference

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

21 January 2018

1 reference

The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin

21 January 2018

1 reference

Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells

21 January 2018

1 reference

The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling.

21 January 2018

1 reference

Prevalence of morning hyperglycaemia: determinants of fasting blood glucose concentrations in insulin-treated diabetics.

21 January 2018

1 reference

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

21 January 2018

1 reference

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

21 January 2018

1 reference

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

21 January 2018

1 reference

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

21 January 2018

1 reference

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

21 January 2018

1 reference

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

21 January 2018

1 reference

Hypoglycemia is the limiting factor in the management of diabetes

21 January 2018

1 reference

Basal and 24-h C-peptide and insulin secretion rate in normal man

21 January 2018

1 reference

7 January 2021

Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia

1 reference

7 January 2021

Crystalline and amorphous insulin-zinc compounds with prolonged action

1 reference

7 January 2021

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

7 January 2021

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

7 January 2021

Optimal provision of daytime NPH insulin in patients using the insulin analog lispro

1 reference

7 January 2021

Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes

1 reference

7 January 2021

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.317

1 reference

5 August 2017

1 reference